
Opinion|Videos|April 10, 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Experts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices?
- What challenges do you anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5


















